• 1
    Ossendorp F, Toes REM, Offringa R, van der Burg SH, Melief CJM. Importance of CD4+ T helper cell responses in tumor immunity. Immunol Lett 2000; 74: 759.
  • 2
    Surman DR, Dudley ME, Overwijk WW, Restifo NP. CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000; 164: 5625.
  • 3
    Keene J, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982; 155: 76882.
  • 4
    Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187: 693702.
  • 5
    Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2- T cells: tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985; 161: 112234.
  • 6
    Greenberg PD. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytotoxic T cells can mediate eradication of disseminated leukemia. J Immunol 1986; 136: 191722.
  • 7
    Dranoff G, Jaffe E, Lazenby P, Golumbek H, Levitsky K, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 353943.
  • 8
    Hung K, Hayahi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998; 188: 235768.
  • 9
    Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181273.
  • 10
    Monach PA, Meredith SC, Siegel CT, Schreiber, H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995; 2: 4559.
  • 11
    Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S. Major histocompatibility complex class II+ B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181: 61729.
  • 12
    Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994; 179: 121524.
  • 13
    Wan Y, Bramson J, Pilon A, Zhu Q, Gauldie J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000; 60: 324753.
  • 14
    Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Apella E, Greg HM, Sette A. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-A. Science 1992; 256: 181720.
  • 15
    Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class-II molecules. Nature 1991; 353: 6227.
  • 16
    Qin Z, Blankenstein T. CD4+ T cell–mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 2000; 12: 67786.
  • 17
    Fischer WH, Straten PT, Terheyden P, Becker JC. Function and dysfunction of CD4+ T cells in the immune response to melanoma. Cancer Immunol Immunother 1999; 48: 36370.
  • 18
    Clemente GC, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 130310.
  • 19
    Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000; 164: 390212.
  • 20
    Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000; 60: 485563.
  • 21
    Le Drean EL, Gervois N, Diez E, Semana G, Dreno B, Jotereau F. HLA class II–restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes. Eur J Immunol 1995; 25: 27326.
  • 22
    Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, et al. Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189: 8716.
  • 23
    Radrizzani M, Benedetti B, Castelli C, Longo A, Ferra GB, Herlyn M, Parmiani G, Fossati G. Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte–melanoma interactions. Int J Cancer 1991; 49: 82330.
  • 24
    Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S, Houghton A. Reactivity of autologous CD4+ T lymphocytes against human melanoma: evidence for a shared melanoma antigen presented by HLA DR15. J Immunol 1995; 154: 7729.
  • 25
    Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus transformed B cells. Int J Cancer 1994; 58: 6970.
  • 26
    Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA. Human CD4+ T cells specially recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91: 94615.
  • 27
    Wang RF. The role of MHC class II–restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001; 22: 26976.
  • 28
    Wang HY, Zhou J, Zhu K, Riker AI, Marincola FM, Wang RF. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med 2002; 195: 1397406.
  • 29
    Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang R-f, Rosenberg SA, Robbins PF. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002; 62: 36305.
  • 30
    Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 1997; 57: 323844.
  • 31
    Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Müller C, Zeuthen J, Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998; 47: 328.
  • 32
    Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893904.
  • 33
    Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997; 7: S3542.
  • 34
    Herlyn D, Iliopoulos D, Jensen P, Parmiter A, Baird J, Hotta H, Adachi K, Ross AH, Jambrosic J, Koprowski H, Herlyn M. In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res 1990; 50: 2296302.
  • 35
    Jacob L, Somasundaram R, Smith W, Monos D, Basak S, Marincola F, Pereira S, Herlyn D. Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells. Int J Cancer 1997; 71: 32532.
  • 36
    Somasundaram R, Robbins P, Moonka D, Loh E, Marincola F, Patel A, Guerry D, Herlyn D. CD4+, HLA class I–restricted, cytolytic T-lymphocyte clone against primary malignant melanoma. Int J Cancer 2000; 85: 2539.
  • 37
    Somasundaram R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, Marks G, Kane M, Mastrangelo M, Herlyn D. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 1995; 155: 325361.
  • 38
    Young JAT, Wilkinson D, Bodmer WF, Trowsdale J. Sequence and evolution of HLA-DR7 and DRw53-associated beta-chain genes. Proc Natl Acad Sci USA 1987; 84: 492933.
  • 39
    Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182: 32331.
  • 40
    Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 247983.
  • 41
    Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56: 474957.
  • 42
    Yang JC, Rosenberg SA. Vaccination trials and response monitoring using the defined melanoma-associated antigen MART-1 and gp100. Melanoma Res 1997; 7: S245.
  • 43
    Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50: 315.
  • 44
    Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 24137.
  • 45
    Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999; 286: 137781.
  • 46
    Guilloux Y, Xue-feng B, Liu X, Zheng P, Liu Y. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 2001; 61: 110712.
  • 47
    Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow–derived cells in presenting MHC class I–restricted tumor antigens. Science 1994; 264: 9615.
  • 48
    LentnerC, ed. Geige Scientific Tables, 8th Ed., Volume 3, Basel, Ciba-Geigy Ltd., 1984, p. 245.
  • 49
    Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H, Iizuka H, Miyokawa N, Katagiri M. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 1998; 58: 296301.
  • 50
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 2002; 62: 2138.
  • 51
    Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL, Sidney J, Sette A, Storkus WJ. Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells. Proc Natl Acad Sci USA 2000; 97: 4005.